Venus Medtech

Venus Medtech is becoming a leading player in structural heart valvular therapies worldwide.
With over 800 employees, more than 800 patent applications, +16,000 implantations and a robust annual R&D investment , we're dedicated to shaping the future of structural heart disease treatment.
Our commitment is to develop a comprehensive product pipeline (TAVR, TPVR, TMVR and TTVR), which covers all four heart valves, offering complete solutions for patients in need.
As key players in this field, Venus Medtech is committed to make a significant impact on the global landscape of heart care.





VenusP-Valve™ System